Both in Biotechnology
Novavax vs Taysha Gene Therapies
Over the past year NVAX returned +27.4% and TSHA returned −7.4%; their daily moves had a correlation of 0.29.
NVAX +27.4% TSHA −7.4%Growth of $1, one year, split-adjusted
| Metric | NVAX | TSHA |
|---|---|---|
| Price | $10.08 | $4.13 |
| Market cap | $1.66B | $1.35B |
| Today | −3.72% | −2.13% |
| 1 month | −4.9% | −12.9% |
| 6 months | +25.4% | −34.8% |
| Year to date | +50.0% | −24.9% |
| 1 year | +20.3% | −17.6% |
| Revenue growth (YoY) | −76.3% | −100.0% |
| Gross margin | 74.9% | — |
| Net margin | −94.2% | — |
| P/E (TTM) | — | — |
| Price / sales | 4.0× | 245.3× |
| Net cash | $422.0M | $406.1M |
| Dividend yield | — | — |
| Volatility (60d) | 79.8% | 58.3% |
| Short % of float | 30.3% | 17.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).